Global Insomnia Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In May 2022, Idorsia Ltd. received marketing approval from the European Commission for QUVIVIQ, a treatment specifically designed for adults suffering from insomnia. This medication is indicated for patients experiencing persistent insomnia for at least three months, with symptoms that significantly affect daily functioning. The approval marks a key milestone for Idorsia, as QUVIVIQ provides a much-needed therapeutic option for individuals struggling with long-term sleep disturbances. With this authorization, the company aims to address the growing demand for effective insomnia treatments and improve the quality of life for patients affected by this condition.

• In January 2022, Idorsia received approval from the United States Food and Drug Administration (FDA) for QUVIVIQ 25 and 50 mg, a treatment specifically designed for adults experiencing insomnia. This medication targets individuals struggling with difficulties in sleep onset and/or maintaining sleep, offering a new therapeutic option to those affected by these common sleep issues. The FDA approval marks a significant milestone for Idorsia, expanding its portfolio of solutions for sleep-related disorders and addressing the growing need for effective treatments in this space.

In this report, the Global Insomnia Market has been segmented by Drug Formulation, Treatment Type, Therapy Type, Diseases Condition, and Geography.

Global Insomnia Market, Segmentation by Drug Formulation

The Global Insomnia Market has been segmented by Drug Formulation into Capsules, Tablet, and Others.

Tablets
Tablets remain the leading formulation in the global insomnia treatment market, capturing about 60% of the total share. Their popularity is driven by their simplicity, precise dosing, and widespread availability in both prescription and over-the-counter options. Tablets are especially preferred for their cost-efficiency in manufacturing and ease of use, making them the go-to choice for long-term and first-line therapy for insomnia across all age groups.

Capsules
Comprising around 25% of the market, capsules are gaining traction due to their quick absorption, smooth swallowing experience, and compatibility with specialized formulations like sustained-release or herbal ingredients. They are commonly used in natural sleep aids and are favored by consumers looking for non-addictive and natural treatment options. This segment is seeing steady growth as awareness increases about alternative remedies and side-effect profiles.

Others
The “Others” category, holding close to 15%, includes innovative formats such as liquids, sprays, gummies, and sublingual strips. These options are gaining attention for their rapid onset of action, flavored delivery, and ease of administration, particularly among children, seniors, and users who struggle with swallowing pills. The segment, while smaller, is expected to expand as consumers seek more personalized and convenient sleep solutions.

Global Insomnia Market, Segmentation by Treatment Type

The Global Insomnia Market has been segmented by Treatment Type into Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others.

Nonbenzodiazepines
Nonbenzodiazepines lead the global insomnia treatment market, capturing close to 38% of the total share. Often referred to as “Z-drugs”, these medications offer effective symptom relief with a lower risk of dependence and minimal residual effects. Popular choices like zolpidem and eszopiclone are widely recommended for short-term management of insomnia. Their balance of efficacy, safety, and quick onset of action has positioned them as the preferred option for both clinicians and patients.

Benzodiazepines and Antidepressants
Benzodiazepines hold about 22% of the market, largely used for short-term intervention in severe insomnia. Despite concerns regarding tolerance and dependence, they remain a viable choice in acute therapeutic scenarios. Antidepressants, which occupy around 18% of the market, are frequently prescribed when insomnia is linked with comorbid mental health conditions. Medications like trazodone are favored for their dual action in treating both mood disorders and sleep disturbances.

Orexin and Melatonin Antagonists
Emerging as innovative therapies, orexin receptor antagonists now account for approximately 10% of the market. These medications target the brain’s wake-promoting system, offering a new pathway to treat insomnia with fewer cognitive side effects. Melatonin antagonists, representing nearly 5%, appeal to users seeking natural sleep regulation. Particularly beneficial for older adults and those with jet lag or circadian rhythm issues, they are gaining ground in both prescription and OTC markets.

Devices and Others
The combined category of devices and alternative treatments represents the remaining 7% of the insomnia market. This includes wearable sleep trackers, electronic stimulation devices, and digital therapies like CBT-based apps. These non-drug options are in demand among patients looking for long-term, side-effect-free solutions. As the emphasis on behavioral health and digital wellness grows, these therapies are poised for sustained expansion.

Global Insomnia Market, Segmentation by Therapy Type

The Global Insomnia Market has been segmented by Therapy Type into Non Pharmacological Therapy and Pharmacological Therapy.

Pharmacological Therapy
Pharmacological therapy continues to dominate the global insomnia treatment market, accounting for nearly 70% of total therapy usage. This category includes widely used medications like benzodiazepines, nonbenzodiazepines, and orexin receptor antagonists, all of which provide fast and effective relief for individuals suffering from insomnia. The high dependency on these medications stems from their quick onset, easy availability, and strong physician preference for managing acute and short-term cases of sleep disorders.

Non-Pharmacological Therapy
Representing around 30% of the market, non-pharmacological therapies are rapidly gaining popularity as awareness grows regarding the risks of long-term medication use. Therapies such as cognitive behavioral therapy for insomnia (CBT-I), mindfulness practices, and sleep hygiene training offer natural, side-effect-free alternatives. These approaches are increasingly being recommended as first-line treatments for chronic insomnia, particularly in healthcare settings that promote behavioral health and wellness.

Global Insomnia Market, Segmentation by DIseases Condition

The Global Insomnia Market has been segmented by DIseases Condition into Poor Quality Of Sleep, Sleep Maintenance, and Others.

Poor Quality of Sleep
Poor quality of sleep represents the largest segment in the global insomnia market, contributing around 48% of diagnosed conditions. Individuals experiencing this issue often suffer from unrefreshing sleep, even after adequate time in bed, resulting in daytime drowsiness and poor concentration. Causes range from psychological stress and anxiety to environmental and lifestyle factors. As this condition impacts a large and diverse population, it continues to drive demand for both clinical interventions and at-home treatment solutions.

Sleep Maintenance
Making up nearly 35% of the market, sleep maintenance insomnia is marked by frequent nighttime awakenings and difficulty returning to sleep. It often affects older individuals and those with underlying conditions such as chronic pain or mental health disorders. This segment is seeing growing adoption of sustained-release medications, behavioral therapies, and sleep hygiene programs designed to enhance sleep continuity and duration.

Other Conditions
The remaining 17% of the market is categorized as Other, encompassing conditions like difficulty falling asleep, circadian rhythm disorders, and secondary insomnia associated with other health issues. These cases often require specialized diagnostics and tailored treatment regimens, including melatonin supplements, light therapy, and CBT-I tools. Increased public awareness and better diagnostic technologies are helping drive growth in this segment.

Global Insomnia Market, Segmentation by Geography

In this report, the Global Insomnia Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Insomnia Market Share (%), by Geographical Region, 2024

North America
North America leads the global insomnia treatment market, capturing nearly 38% of the total share during the forecast period of 2021 to 2031. The region's dominance is supported by the rising prevalence of stress-related disorders, anxiety, and poor sleep hygiene. The widespread availability of advanced treatment options, strong insurance coverage, and the presence of leading pharmaceutical players contribute to high treatment uptake in the U.S. and Canada.

Europe
Accounting for approximately 28% of the global insomnia market, Europe benefits from growing awareness around sleep disorders, a rising number of elderly individuals, and increased use of CBT-I and other non-drug interventions. The region is bolstered by favorable healthcare policies, especially in countries like Germany, France, and the UK, which support both medication and therapy-based approaches. The market is also influenced by proactive public health strategies promoting mental wellness.

Asia Pacific
With a market share of around 22%, the Asia Pacific region is experiencing rapid growth due to an upsurge in urban stress, expanding healthcare access, and a growing focus on mental health awareness. Countries such as China, India, and Japan are leading this regional surge, driven by the increasing adoption of both conventional and alternative treatments for insomnia. Local pharmaceutical innovation and affordable treatment options are helping penetrate underserved markets.

Middle East & Africa and Latin America
Together accounting for nearly 12%, Middle East & Africa and Latin America represent emerging regions with untapped potential. These areas are witnessing slow but steady increases in diagnosis and treatment of insomnia due to rising urbanization, healthcare infrastructure development, and growing consumer interest in wellness and lifestyle management. As awareness improves, these markets are expected to contribute more significantly to global growth in the coming years.

This report provides an in depth analysis of various factors that impact the dynamics of Global Insomnia Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Aging Population
• Increased Awareness
• Growth in Mental Health Disorders

• Advancements in Therapeutics - Advancements in therapeutics are significantly driving the growth of the global insomnia market, providing patients with more effective and targeted treatment options. Innovations in pharmacological treatments, including the development of new classes of medications such as dual orexin receptor antagonists (DORAs), offer improved efficacy and safety profiles compared to traditional benzodiazepines and non-benzodiazepine hypnotics. These advancements address common issues such as the risk of dependency and adverse side effects, enhancing patient adherence and satisfaction with their insomnia treatments.

  The advent of personalized medicine is transforming insomnia therapy by allowing for treatments tailored to individual patient profiles. Genetic and biomarker research is paving the way for the development of personalized treatment plans that consider a patient's unique genetic makeup, lifestyle, and specific sleep disorder characteristics. This approach increases the likelihood of treatment success and reduces the risk of adverse reactions, making it a promising direction for future insomnia therapeutics.

  Advancements in non-pharmacological therapies, such as cognitive behavioral therapy for insomnia (CBT-I) delivered through digital platforms, are expanding treatment options for patients. Digital health technologies, including mobile apps and telemedicine, provide convenient access to evidence-based therapies that can be customized and scaled to meet the needs of diverse populations. These innovations not only improve accessibility and affordability of insomnia treatments but also promote long-term management of sleep disorders, contributing to the overall growth and development of the global insomnia market.

Restraints

• High Cost of Treatment
• Risk of Dependency
• Limited Availability of Effective Therapies

• Stringent Regulatory Requirements - Stringent regulatory requirements present a significant challenge in the global insomnia market, impacting the development, approval, and commercialization of new therapies. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce rigorous standards to ensure the safety, efficacy, and quality of insomnia medications and treatments. These stringent requirements often lead to prolonged development timelines and increased costs for pharmaceutical companies, potentially delaying the availability of innovative therapies to patients.

  The extensive clinical trials and comprehensive documentation needed to meet regulatory standards are particularly burdensome for smaller biotech and pharmaceutical firms with limited resources. These companies must invest heavily in research and development, as well as in regulatory affairs expertise, to navigate the complex approval processes. Additionally, the requirement for post-marketing surveillance and ongoing safety monitoring adds to the long-term financial and operational burden, affecting the overall market dynamics and competition.

  Varying regulatory requirements across different regions add another layer of complexity for companies aiming to launch insomnia treatments globally. Harmonizing these regulations to streamline the approval process remains a significant challenge. Despite these obstacles, stringent regulatory requirements are essential for ensuring that new insomnia treatments are safe and effective for patients. However, the industry must continuously adapt and innovate to meet these challenges while advancing the development of new therapies to address the unmet needs of insomnia sufferers worldwide.

Opportunities

• Growing Demand for Natural Remedies
• Expansion in Emerging Markets
• Research and Development Investments

• Personalized Medicine Approaches - Personalized medicine approaches are revolutionizing the treatment landscape of the global insomnia market by tailoring therapies to individual patient needs. This method involves using genetic, environmental, and lifestyle information to design and optimize treatment plans specifically suited to each patient. By identifying genetic markers and other individual characteristics that influence how patients respond to various treatments, healthcare providers can prescribe the most effective medications and therapeutic interventions, thereby enhancing treatment outcomes and minimizing adverse effects.

  Personalized medicine in insomnia treatment is the ability to move away from a one-size-fits-all approach. Traditional insomnia therapies often rely on a trial-and-error process to find the right medication and dosage, which can be time-consuming and frustrating for patients. Personalized medicine, on the other hand, allows for a more precise and targeted approach, reducing the likelihood of ineffective treatments and helping patients achieve better sleep more quickly. This approach can significantly improve patient satisfaction and adherence to treatment regimens.

  Advancements in technology and data analytics are facilitating the implementation of personalized medicine in insomnia care. Tools such as genetic testing, wearable sleep trackers, and artificial intelligence algorithms enable the collection and analysis of detailed patient data. This information can be used to identify specific sleep patterns, potential triggers for insomnia, and the best therapeutic strategies. As personalized medicine continues to evolve, it holds the promise of transforming insomnia treatment by providing more accurate, efficient, and individualized care, ultimately improving the quality of life for millions of people affected by sleep disorders.

Key players in Global Insomnia Market include :

• Pfizer Inc
• Takeda Pharmaceutical Company Ltd
• Sanofi S.A
• Idorsia Pharmaceuticals Ltd
• Electromedical
• Merck & Co
• Aurobindo Pharma Limited
• Astellas Pharma

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis